Arcturus Shares Surge Amid Progress in Mid-Stage Clinical Trials

Arcturus Therapeutics shares rose by 9.8% on Tuesday following the initiation of dosing in two mid-stage clinical trials. On Monday, Arcturus announced the commencement of dosing in Phase 2 multiple ascending dose studies for Cystic Fibrosis (CF) and Ornithine Transcarbamylase (OTC) deficiency. This development positions Arcturus to release interim results in the first half of this year. The shares of the biotechnology firm, which experienced a decline of approximately 50% throughout 2024, have now risen for the fifth consecutive day. "ARCT-032 has the potential to address a significant unmet medical need in the CF community, which is underserved or not benefiting from current treatment options," stated Pad Chivukula, Arcturus's Chief Scientific Officer, in a press release. As the market anticipates interim results from the clinical trials, the current upward trend in Arcturus Therapeutics' stock price underscores the critical importance of clinical milestones in determining the valuations of biotechnology companies.